These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 22718839)

  • 1. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
    Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
    Li W; Chang Y; Liu X; Chen Z; Sun J; Geng Z; Zhang M; Zhang L
    Ann Hematol; 2024 Jun; 103(6):2003-2012. PubMed ID: 38308020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
    Dreyling M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; Hänel M; Dierlamm J; Pott C; Klapper W; Gözel D; Schmidt C; Unterhalt M; Ladetto M; Hoster E
    Lancet; 2024 May; 403(10441):2293-2306. PubMed ID: 38705160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
    J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
    [No Abstract]   [Full Text] [Related]  

  • 6. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
    Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
    Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
    Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
    J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
    Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M
    Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
    Lefrère F; Delmer A; Levy V; Delarue R; Varet B; Hermine O
    Haematologica; 2004 Oct; 89(10):1275-6. PubMed ID: 15477221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
    Reddy N; Greer JP; Goodman S; Kassim A; Morgan DS; Chinratanalab W; Brandt S; Englehardt B; Oluwole O; Jagasia MH; Savani BN
    Exp Hematol; 2012 May; 40(5):359-66. PubMed ID: 22269117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.